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ABSTRACT Cryptococcal meningitis is a lethal disease with few therapeutic options.
Induction therapy with ﬂuconazole has been consistently demonstrated to be associ-
ated with suboptimal microbiological and clinical outcomes. Exposure to ﬂuconazole
causes dynamic changes in antifungal susceptibility, which are associated with the
development of aneuploidy. The implications of this phenomenon for pharmacody-
namics of ﬂuconazole for cryptococcal meningitis are poorly understood. The phar-
macodynamics of ﬂuconazole were studied using a hollow-ﬁber infection model
(HFIM) and a well-characterized murine model of cryptococcal meningoencephalitis.
The relationship between drug exposure and both antifungal killing and the emer-
gence of resistance was quantiﬁed. The same relationships were further evaluated in
a recently described group of patients with cryptococcal meningitis undergoing in-
duction therapy with ﬂuconazole at 800 to 1,200 mg/day. The pattern of emergence
of ﬂuconazole resistance followed an “inverted U.” Resistance ampliﬁcation was max-
imal and suppressed at ratios of the area under the concentration-time curve for the
free, unbound fraction of the drug to the MIC (fAUC:MIC) of 34.5 to 138 and 305.6, re-
spectively. Emergence of resistance was observed in vivo with an fAUC:MIC of 231.4. An-
euploidy with duplication of chromosome 1 was demonstrated to be the underlying
mechanism in both experimental models. The pharmacokinetic (PK)-pharmacodynamic
model accurately described the PK, antifungal killing, and emergence of resistance.
Monte Carlo simulations from the clinical pharmacokinetic-pharmacodynamic model
showed that only 12.8% of simulated patients receiving ﬂuconazole at 1,200 mg/day
achieved sterilization of the cerebrospinal ﬂuid (CSF) after 2 weeks and that 83.4%
had a persistent subpopulation that was resistant to ﬂuconazole. Fluconazole is pri-
marily ineffective due to the emergence of resistance. Treatment with 1,200 mg/day
leads to the killing of a susceptible subpopulation but is compromised by the emer-
gence of resistance.
IMPORTANCE Cryptococcal meningitis is a lethal disease with few treatment options.
The incidence remains high and intricately linked with the HIV/AIDS epidemic. In many
parts of the world, ﬂuconazole is the only agent that is available for the initial treat-
ment of cryptococcal meningitis despite considerable evidence that it is associated
with suboptimal microbiological and clinical outcomes. Fluconazole has a fungistatic
mode of action: it predominantly inhibits growth rather than causing fungal killing.
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Our work shows that the pattern of ﬂuconazole activity is caused by the emergence
of resistance in Cryptococcus not detected by standard susceptibility tests, with chro-
mosomal duplication/aneuploidy as the main mechanism. Resistance emergence is
related to drug exposure and occurs with the use of clinically relevant regimens.
Hence, ﬂuconazole (and potentially other agents that target 14-alpha-demethylase)
is compromised by an intrinsic property that limits its effectiveness. However, this
resistance may be potentially overcome by dosage escalation or the use of combina-
tion therapy.
KEYWORDS antifungal resistance, antimicrobial resistance, cryptococcus, ﬂuconazole,
fungus, meningitis, yeast
Fluconazole is a mainstay for the treatment of cryptococcal meningitis: it has anextensive safety usage database, is orally bioavailable, has excellent central nervous
system (CNS) penetration, has few clinically relevant drug-drug interactions, and has a
plethora of clinical data for its use. Unlike amphotericin B and ﬂucytosine (5FC), the
other two antifungal agents recommended for therapy of cryptococcal meningitis (1),
ﬂuconazole is the only drug available in much of Africa, where cryptococcal meningitis
is most prevalent (2). However, ﬂuconazole monotherapy, even when used at high
doses of 800 to 1,200 mg/day (3), is associated with low rates of fungal clearance in the
cerebrospinal ﬂuid (CSF) and suboptimal clinical outcomes compared with amphoter-
icin B-based therapy or combinations with ﬂucytosine. One-year mortality approaches
70% in African cohorts (4–7). Historically, this has been attributed to a fungistatic
pattern of antifungal activity, whereby inhibition of growth is observed rather than
orders of logarithmic CSF yeast killing. Recent insights into the pharmacodynamics of
ﬂuconazole against Cryptococcus neoformans (8) and a better understanding of the
molecular mechanisms of resistance (9) suggest that this concept is overly simplistic.
Primary cryptococcal resistance to high-level ﬂuconazole caused by a stable herita-
ble genetic mechanism appears to be relatively rare. However, clinical relapses with
isolates possessing reduced susceptibility to ﬂuconazole commonly occur in the setting
of monotherapy (10). For instance, C. neoformans displays heteroresistance to ﬂucona-
zole; i.e., there is a resistant subpopulation present even in the absence of the drug,
which is so small (often 1%) that it may be missed by conventional antifungal
susceptibility (MIC) testing. Following drug exposure, this subpopulation expands (or at
least persists) during drug therapy, while the susceptible yeast subpopulation is killed
(11). Partial and complete duplications of chromosome 1 are most commonly observed
in this resistant subpopulation; however, other disomies have also been reported (12,
13). While aneuploidy has been demonstrated in preclinical (12) and, more recently,
clinical (13) contexts, the pharmacodynamics (PD) of this phenomenon are not well
understood. A better understanding of the relationship between ﬂuconazole exposure
and the emergence of resistance is required to further optimize ﬂuconazole-based
regimens for the treatment of cryptococcal meningitis.
Several studies have examined the relationship between in vitro ﬂuconazole sus-
ceptibility and clinical outcomes for informing clinical breakpoints (14). Others have
formally described the population pharmacokinetics (PK) of ﬂuconazole in human
plasma and CSF (15). However, none have combined fungal in vitro susceptibility
testing and molecular mechanisms of resistance with direct antifungal drug exposures
at the site of infection and then linked these variables with microbiological outcomes
such as fungal killing and the emergence of resistance. In this study, we used several
preclinical experimental platforms and a clinical PK-PD study to explore the pharma-
codynamics of ﬂuconazole in the treatment of cryptococcal meningitis when adminis-
tered as induction monotherapy. We used a recently described hollow-ﬁber infection
model (HFIM) of cryptococcal meningitis (16) in which simulation of concentration-time
proﬁles of ﬂuconazole in CSF enables the full exposure-response relationships for
ﬂuconazole-susceptible and -resistant subpopulations at the site of infection to be
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delineated. These in vitro ﬁndings were then conﬁrmed in a well-characterized murine
model of cryptococcal meningitis and further linked to a clinical PK-PD substudy.
RESULTS
Strains, mutational frequency of resistance, and detection of resistance. H99
(ATCC 208821) was used as the challenge strain in the hollow-ﬁber infection model and
murine model of cryptococcal meningitis. The ﬂuconazole MIC was 4 mg/liter using
Clinical and Laboratory Standards Institute (CLSI) microdilution methodology (17). The
mutational frequency of resistance was 8 104 at 32mg/liter of ﬂuconazole. Concentra-
tions of 32 and 64mg/liter were incorporated into yeast extract-peptone-dextrose (YPD)
agar for the detection of resistance in the hollow-ﬁber andmurine experiments. Aneuploidy
of chromosome 1 was observed in isolates able to grow on agar containing ﬂuconazole at
32mg/liter (Fig. 1).
Hollow-ﬁber infection model. The shape of the ﬂuconazole concentration-time
proﬁle in human CSF was reproduced in the hollow-ﬁber infection model. Different
concentration-time proﬁles with the same overall shape were generated to enable the
pharmacodynamics for both susceptible and resistant subpopulations to be explored
and quantiﬁed. Treatment was delayed for 24 h postinoculation. Low exposures of
ﬂuconazole resulted in some decrease in the total fungal burden, but this was offset by
the emergence of a resistant subpopulation that was able to grow on agar containing
ﬂuconazole at 32 and 64 mg/liter (Fig. 2A, panel b). For a ratio of the area under the
concentration-time curve for the free, unbound fraction of the drug to the MIC
(fAUC:MIC) in the range 34.5 to 138 (Fig. 2A, panels c and d), almost all of the fungal
burden at the end of the experiment consisted of resistant yeasts able to grow on agar
containing ﬂuconazole at 64 mg/liter. In the case of Fig. 2A, panel d, 93% of the total
population was highly resistant. Fluconazole exposures of an fAUC:MIC of 305.6
resulted in the killing of both the susceptible and resistant subpopulations and apparent
sterilization of the cartridge (Fig. 2A, panel e). A plot of the fAUC:MIC within the CSF versus
the fungal burden of the resistant colonies at the end of the experiment revealed an
“inverted U,” which is characteristic of many drug exposure-versus-resistance relationships
(18) (Fig. 2A, panel f).
Samples from the cartridge at the beginning and end of the HFIM experiment were
cultured on drug-free YPD (i.e., unselected) agar incubated at 30°C in air. A sweep of
colonies was selected for sequencing. Unselected isolates at the beginning of the
experiment (prior to exposure to ﬂuconazole) did not have aneuploidy (Fig. 2B, panel
a). Similarly, colonies from the control arm at the end of the experiment did not have
aneuploidy (Fig. 2B, panel b). In contrast, unselected colonies obtained at the end of the
experiment from arms c and d (fAUC:MIC of 70.85 and 138, respectively) had aneu-
ploidy with partial and complete duplications of chromosome 1, respectively. Both
duplications involved the ERG11 gene, which encodes the triazole target lanosterol
14--demethylase. Unexpectedly, aneuploidy was not demonstrated in arm b despite
the emergence of phenotypic resistance, which may have been due to either missing
the resistant subpopulation (i.e., a smaller fraction of resistant organisms than in arms
c and d) or an alternative molecular mechanism of resistance unrelated to aneuploidy.
FIG 1 Association between aneuploidy and the ability of C. neoformans to grow on agar containing 32 mg/liter ﬂuconazole (FLC).
Sequence reads are mapped against the reference genome. Blackout of a chromosome indicates a 2-fold increase in copy number.
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FIG 2 (A) Pharmacodynamics of ﬂuconazole against Cryptococcus neoformans H99 (ﬂuconazole MIC of 4 mg/liter) in a hollow-ﬁber infection model.
Treatment was delayed for 24 h postinoculation. (a to e) Time courses of different populations in response to different concentration-time proﬁles of
(Continued on next page)
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Murine studies of cryptococcal meningoencephalitis. The in vivo pharmacody-
namics of ﬂuconazole against Cryptococcus neoformanswere studied in a well-characterized
murine model of meningoencephalitis. PK-PD relationships were established over the
course of multiple independently conducted experiments. The dosages of ﬂuconazole
used for the PK and PD studies were determined from preliminary experiments (see
Fig. S1 in the supplemental material) and previously reported studies (8).
The pharmacokinetics of ﬂuconazole in plasma and cerebrum using dosages of 125
and 250 mg/kg of body weight/day administered by oral gavage are shown in Fig. 3A
and B. A dose of 250 mg/kg/day was limited by the maximum volume that can be
administered by oral gavage under the terms of our laboratory animal license. The total
plasma drug AUC:MIC value associated with the administration of 250 mg/kg/day was
260 (i.e., an fAUC:MIC of 231.4 assuming 11% protein binding in the mouse). The
dose-response relationship using the total fungal burden as the pharmacodynamic
endpoint was established using 25, 50, 125, and 250 mg/kg/day orally (Fig. S1). The
emergence of resistance was explored using a destructive design with controls and a
single dosage of ﬂuconazole at 250 mg/kg day orally and plating murine brain homog-
enates onto YPD agar containing ﬂuconazole at 32 mg/liter (Fig. 3C and D). A dosage
of 250 mg/kg/day consistently resulted in a logarithmic reduction of the cerebral fungal
burden relative to controls (Fig. 3D). The emergence of resistance was observed in
untreated controls in a ﬁxed proportion to the total fungal burden (Fig. 3C). The
emergence of resistance (deﬁned as the ability to grow on agar containing ﬂuconazole
at 32 mg/liter) was observed in mice receiving 250 mg/kg/day in the second week of
the experiment, at between 192 and 240 h postinoculation, which was consistent with
observations from the HFIM. The use of agar containing ﬂuconazole at 64 mg/liter
resulted in inconsistent results, where some experiments showed an emergence of
resistance, while others did not (Fig. S2). The variability in the emergence of resistance
in these experiments is probably explained by cells with aneuploidy not being within the
CNS immediately postinoculation, or the in vivo rate of development of duplication not
present immediately postinoculation was 240 h. A higher fungal density (i.e., greater
than the mutational frequency) at the time of treatment initiation may have resulted in
more consistency in the emergence of resistance. This could have been facilitated by
delaying the initiation of therapy or inoculation directly into the CNS as described by
others (see, for example, reference 19). The chromosomal ploidy map from colonies
sequenced from murine brain homogenates plated onto ﬂuconazole-containing agar
demonstrated the emergence and persistence of chromosome 1 disomy after 96 h of
ﬂuconazole exposure (Fig. 3B).
The parameters for the mathematical model that links the dosage of ﬂuconazole
with plasma concentrations, concentrations in brain, the decline in total fungal
burden in the brain, and the emergence of a resistant subpopulation are summa-
rized in Table 1. The Bayesian posterior values from each individual (i.e., cohort of mice
under the same experimental conditions) were used to ﬁt the mathematical model to
the PK and PD data shown in Fig. 3.
Clinical study of ﬂuconazole as induction therapy for cryptococcal meningo-
encephalitis. A total of 17 patients receiving ﬂuconazole as induction therapy for cryp-
tococcal meningitis were enrolled and studied in Tanzania. The clinical characteristics
are shown in Table 2. Patients received 800 to 1,200 mg ﬂuconazole orally (or intrave-
nously [i.v.]) as induction therapy in a single or divided dosage administered every 12 h.
FIG 2 Legend (Continued)
ﬂuconazole in CSF that mimic those in humans. Black, total cryptococcal population; red, resistant subpopulation able to grow on agar containing
ﬂuconazole at 32 mg/liter; blue, resistant subpopulation able to grow on agar containing ﬂuconazole 64 mg/liter. (f) The relationship between fAUC:MIC
and the resistant fungal density at the end of the experiment shows an “inverted U.” (B) Chromosome map (Y-map). (a) Ploidy map of the inoculating
strain (before ﬂuconazole exposure) showing monosomy. Colonies taken from drug-free YPD agar do not show aneuploidy, but a colony taken from
ﬂuconazole-containing agar shows disomy of chromosome 1. (b to e) Y-maps of colonies taken at the end of the hollow-ﬁber infection model
experiment (264 h for all arms except arm e, for which 144 h was the last culture-positive time point. In arm c, partial duplication of chromosome 1 is
apparent, while complete disomy of chromosome 1 is seen in arm d. The duplicated region of chromosome 1 in arm c contains the ERG11 gene, the
ﬂuconazole target. For the control (arm a), the lowest dose (arm b), and the highest dose (arm e), no aneuploidy is observed in unselected colonies,
suggesting that ampliﬁcation of the resistant, chromosome 1 disomic subpopulation occurs with moderate exposures to ﬂuconazole.
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A three-compartment pharmacokinetic model consisting of gut, plasma, and CSF
was used to describe the concentration-time course of ﬂuconazole administered orally
or i.v. in the plasma and CSF (Table 3). Of the 17 patients, one was excluded because
there was only a single PK measurement. The remaining 16 patients were well
described by this model, with coefﬁcients of determination (r2) for the linear regression
of observed-predicted values after the Bayesian step for the plasma and CSF of 0.58 and
0.77, respectively. The Bayesian posterior estimates for each patient were used to
FIG 3 Representative murine PK-PD experiments. (A and B) Murine PK in plasma (raw data are shown as solid squares, and model ﬁt is shown with a solid line)
and cerebrum (open squares and broken line) following the administration of ﬂuconazole at 125 and 250 mg/kg/day, respectively, by oral gavage. Data are
means and standard deviations for 3 mice. (C and D) Pharmacodynamics for controls (C) and ﬂuconazole at 250 mg/kg/day (D). The closed and open squares
are the raw data from the total and drug-resistant subpopulations, respectively. For both controls (C) and drug-treated mice (D), emergence of resistance was
not observed until relatively late in the experiment. The solid and broken lines are the model ﬁts from the mean Bayesian posterior estimates for the total and
resistant subpopulations, respectively. The bottom panel shows a Y-map (chromosome map) of Cryptococcus neoformans H99 grown from brain homogenates.
(E) There was no resistant subpopulation within the inoculum because it was either truly absent or below the limit of detection. (F) Colonies from control mice
growing on ﬂuconazole-containing agar had aneuploidy at 192 h. (G) Colonies from mice receiving ﬂuconazole at 250 mg/kg/day and growing on
ﬂuconazole-containing agar had aneuploidy at 192 h. Sequencing of colonies growing on ﬂuconazole-containing agar showed disomy of the chromosome in
all cases.
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calculate the percent partitioning into CSF. The mean partitioning of total drug
ﬂuconazole from the plasma into the CSF  standard deviation was 94.54%  29.59%,
with a range of 46.38 to 170.97%. With correction for protein binding, the partitioning
was 106.22%  33.24% The shape of the concentration-time curve in the CSF was
similar to that in plasma, without evidence of hysteresis (data not shown).
TABLE 1 Parameter values and dispersions from the mathematical model ﬁtted to murine
PK-PD data
Parametera
Value
Mean Median SD
Ka (h1) 0.974 0.974 0.052
SCL/F (liters/h) 0.006 0.006 0.000
V/F (liters) 0.008 0.008 0.001
Kcp (h1) 2.391 2.391 0.026
Kpc (h1) 15.667 15.667 4.741
Kcs (h1) 18.853 18.853 5.959
Ksc (h1) 11.872 11.872 1.736
Vcns/f (liters) 0.024 0.024 0.009
Kgmax_s (log10 CFU/g/h) 0.078 0.080 0.014
popmax (CFU/g) 26,294,350.171 42,296,494.976 22,574,600.414
kkmax_s (log10 CFU/g/h) 0.257 0.279 0.022
C50k_s (mg/liter) 25.090 23.496 1.641
Hk_s 15.252 14.323 1.167
Kgmax_r (log10 CFU/g/h) 0.032 0.026 0.007
kkmax_r (log10 CFU/g/h) 1.469 1.716 0.436
C50k_r (mg/liter) 88.795 89.265 1.809
Hk_r 18.989 19.822 0.950
IC_s (CFU/g) 148.570 144.106 17.730
IC_r (CFU/g) 9.230 10.000 1.493
aParameters are as follows: Ka is the ﬁrst-order rate constant that connects the gut to the bloodstream; SCL
is the ﬁrst-order clearance of ﬂuconazole from the central compartment (i.e., bloodstream); V is the volume
of the central compartment; Kcp and Kpc are the ﬁrst-order intercompartmental rate constants that connect
the central and peripheral compartments; Ksc and Kcs are the ﬁrst-order intercompartmental rate constants
that connect the central compartment and CSF; Vcns is the volume of the CSF; F is the oral bioavailability
of ﬂuconazole; Kgmax_s and Kgmax_r are the maximum growth rates of the susceptible and resistant
subpopulations, respectively; popmax is the maximum theoretical fungal density in the cerebrum; kkmax_s
is the maximum rate of ﬂuconazole killing of the susceptible subpopulation in the cerebrum; C50k_s is the
cerebral concentration of ﬂuconazole at which the rate of killing of the susceptible subpopulation is half
maximal; Hk_s is the slope function for the effect of ﬂuconazole on the susceptible population; kkmax_r is
the maximum rate of ﬂuconazole killing of the resistant subpopulation in the cerebrum; C50k_r is the
cerebral concentration of ﬂuconazole at which the rate of killing of the resistant subpopulation is half
maximal; Hk_r is the slope function for the effect of ﬂuconazole on the resistant population; and IC_s and
IC_r are the estimated initial densities of the susceptible and resistant subpopulations in the cerebrum,
respectively.
TABLE 2 Characteristics of the 16 patients included in the pharmacokinetic study
Parameter Value
Total no. of patients included 16
No. of male patients 6
No. of female patients 10
Age range (yr) 19–56
Median no. of CD4 cells/mm3 (IQRa) 28 (142–83)
No. (%) of patients with GCSb  15 8 (50)
No. (%) of patients with CSF opening pressure of 20 cm H2O 10 (63)
Median baseline fungal burden (CFU/ml CSF) (IQR) 11,200 (390–63,000)
Mortality [no. (%) of patients who died/total no. of patients]
2 wk 1/16 (6)
10 wk 4/12 (33)c
1 yr 5/12 (42)
aIQR, interquartile range.
bGCS, Glasgow coma scale.
cFour patients were lost to follow-up at between 2 and 10 weeks.
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A subset of 11 patients had concomitantly collected pharmacodynamic data follow-
ing prespeciﬁed lumbar punctures (LPs) as well as additional procedures for man-
agement of raised intracranial pressure. Patients had a median of 3 lumbar punc-
tures (range, 1 to 7) within the ﬁrst 14 days of treatment, with limited numbers of
observations for patients dying early. Details of the MICs and clinical outcomes are
summarized in Table 4. The pharmacodynamic model ﬁtted to these data is shown in
Table 5. The MICs of ﬂuconazole for clinical isolates from these lumbar punctures varied
with the methodology used and timing of the test, i.e., immediate Etest performed
on-site in Tanzania versus broth microdilution following several freeze-thaw cycles.
Etest MICs were consistently higher than microdilution MICs, with modal MICs of 4
versus 1 mg/liter, respectively.
The raw pharmacodynamic data from each patient (patients A to R) are shown in
Fig. 4 (note that these data have been previously reported [13]). The PK and PD data
from the 11 patients were sufﬁcient to ﬁt a PK-PD model that described the time course
of both the total (Fig. 4, black lines) and resistant (red lines) fungal subpopulations.
Fluconazole did not achieve sterilization in 10/11 patients, with persistence of an underlying
resistant subpopulation able to grow on agar containing ﬂuconazole at 32 mg/liter.
There was, however, considerable heterogeneity between patients. In the majority, the
resistant subpopulation declined with ﬂuconazole therapy, and in patients J, N, and R,
there was an expansion of the resistant subpopulation, whereas in patients H, K, and O,
the total population consisted entirely of a resistant subpopulation after the susceptible
population was killed (Fig. 4). The fAUC:MIC in CSF for each patient was calculated using
TABLE 3 PK parameters for 16 patients with 1 ﬂuconazole PK data sample available
from plasma and CSF
Parametera
Value
Mean Median SD
Ka (h1) 4.383 1.031 6.483
SCL (liters/h) 0.794 0.624 0.303
V (liters) 18.136 10.464 11.302
Kcp (h1) 10.341 0.260 12.674
Kpc (h1) 15.603 14.915 7.905
Kcs (h1) 27.805 27.189 13.131
Ksc (h1) 35.756 39.671 10.776
Vcsf (liters) 16.293 13.425 14.369
F 0.903 1.000 0.152
aParameters are as follows: Ka is the ﬁrst-order rate constant that connects the gut to the bloodstream, SCL
is the ﬁrst-order clearance of ﬂuconazole from the central compartment (i.e., bloodstream), V is the volume
of the central compartment, Kcp and Kpc are the ﬁrst-order intercompartmental rate constants that connect
the central and peripheral compartments, Ksc and Kcs are the ﬁrst-order intercompartmental rate constants
that connect the central and CSF compartments, Vcsf is the volume of the CSF, and F is the oral
bioavailability of ﬂuconazole.
TABLE 4 Demographics, MICs, and clinical outcomes of the 11 patients in the pharmacokinetic-pharmacodynamic substudy
Patient
Patient in study
by Stone et al.a Age (yr) Sex
MIC (mg/liter) (by
broth microdilution) Outcomeb
A 001 19 F 2 Alive at 12 mo
B 002 35 M 1 Alive at 12 mo
F 007 37 M 1 Died at 3 mo
G 008 33 F 1 Alive at day 14 and then LFU
H 009 40 M 1 Died at 3 mo
J 010 48 F 1 Alive at day 11 and then LFU
K 011 42 M 1 Culture negative at day 14; died at 1 mo
N 014 31 F 1 Alive at day 5 and then LFU
O 015 50 F 0.25 Alive at 12 mo
Q 017 45 F 0.25 Alive at 2 wk and then LFU
R 018 40 F 2 Died at 1 mo
aSee reference 13.
bLFU, lost to follow-up.
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the MIC obtained using broth microdilution. Some of the variability in pharmacody-
namics and expansion of a resistant clone(s) despite the attainment of an fAUC:MIC of
305 may be due to strain-to-strain differences in heteroresistance, mutational fre-
quency, and the distribution of the MICs of emergent less susceptible subpopulations.
Hence, there are clearly limitations in the use of a single MIC estimate that is assumed
to be invariant for the pharmacodynamic analyses.
Monte Carlo simulations performed in Pmetrics (20) allowed the potential conse-
quences of a much larger population of patients receiving 1,200 mg ﬂuconazole daily
to be explored. More speciﬁcally, the simulations provided an estimate of the propor-
tion of simulated patients that achieved sterilization after induction therapy and the
variability of the fungal density-versus-time plots for both the total population and the
resistant subpopulation. Simulations performed with the PK-PD model highlighted that
the median fungal density-versus-time proﬁle showed only a minor decline in fungal
density with time (Fig. 5). Furthermore, only 12.8% of simulated patients achieved
sterilization (i.e., log10 CFU of 1/ml CSF) at 14 days (336 h) posttherapy. Resistant
colonies were detectable (log10 CFU of 1/ml CSF) at various densities in 83.4% of
patients at the end of induction therapy. Hence, the simulations reﬂected the PK-PD
data from the Tanzanian clinical study (9% sterilization) and were comparable with
microbiological data from two prior clinical African cohorts receiving ﬂuconazole mono-
therapy at 1,200mg/day showing 2-week CSF sterilization in 6% and 18% of patients,
respectively (3, 4).
DISCUSSION
This pharmacokinetic-pharmacodynamic study demonstrates that ﬂuconazole at
clinically relevant exposures fails to sterilize the CNS and is ineffective at preventing the
rapid emergence of resistance. Aneuploidy is the predominant mechanism, although
other mechanisms are also likely to be operational. The study is unique in that it combines
information from experimental models of cryptococcal meningitis with data from patients
receiving ﬂuconazole as monotherapy, which remains the norm in much of Africa
despite not being consistent with current treatment recommendations from the WHO
(1). The relatively poor microbiological clearance and ultimate clinical outcome follow-
ing induction with ﬂuconazole as a single agent have traditionally been attributed to
a fungistatic pattern of killing. Here, we show that part of the reason for this microbi-
ological failure is related to the emergence of resistance and that this in turn can be
linked to the magnitude of ﬂuconazole drug exposure.
TABLE 5 Pharmacodynamic parameters for 11 patients with 1 estimate of fungal
density from CSF
Parametera
Value
Mean Median SD
popmax (CFU/ml) 9,066,008.322 9,986,903.386 2,745,844.217
kkmax_s (log10 CFU/ml/h) 0.101 0.035 0.114
C50k_s (mg/liter) 35.563 37.687 13.324
Hk_s 12.409 13.691 6.858
Kgmax_r (log10 CFU/ml/h) 0.031 0.030 0.001
kkmax_r (log10 CFU/ml/h) 0.039 0.041 0.013
C50k_r (mg/liter) 14.702 10.897 12.898
Hk_r 18.020 18.510 1.882
Initial Condition_s (CFU/ml) 89,543.363 11,218.526 133,792.013
Initial Condition_r (CFU/ml) 304.542 94.955 373.212
aParameters are as follows: popmax is the maximum theoretical fungal density in CSF; kkmax_s is the
maximum rate of ﬂuconazole killing of the susceptible subpopulation in CSF; C50k_s is the CSF
concentration of ﬂuconazole at which the rate of killing of the susceptible subpopulation is half maximal;
Hk_s is the slope function for the effect of ﬂuconazole on the susceptible population; Kgmax_r is the
maximum rate of growth of the resistant subpopulation; kkmax_r is the maximum rate of ﬂuconazole killing
of the resistant subpopulation in CSF; C50k_r is the CSF concentration of ﬂuconazole at which the rate of
killing of the resistant subpopulation is half maximal; Hk_r is the slope function for the effect of ﬂuconazole
on the resistant population; and Initial Condition_s and Initial Condition_r are the estimated initial densities
of the susceptible and resistant subpopulations in the CSF, respectively.
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The information on the pharmacodynamics of ﬂuconazole obtained from the dif-
ferent model systems was complementary. The hollow-ﬁber infection model enabled
the full range of pharmacodynamic responses to be delineated and suggests that an
fAUC:MIC of 305.7 in CSF results in suppression of resistance. An inverted U suggests
that it may be at least theoretically possible to generate ﬂuconazole exposures in CSF
that are sufﬁciently high to achieve fungicidal activity and minimize the emergence of
resistance, although this would likely be at the expense of increased toxicity. A trial
examining higher dosages of ﬂuconazole (1,600 and 2,000 mg/day [ClinicalTrials.gov
identiﬁer NCT00885703]) has completed enrollment, and preliminary results are avail-
able (https://clinicaltrials.gov). If higher dosages were to be associated with improved
microbiological and clinical outcomes, further PK-PD studies would be required to
conﬁrm the pharmacokinetic linearity of ﬂuconazole, the linear partitioning of ﬂucona-
FIG 4 Time course of pharmacodynamics for patients with cryptococcal meningitis receiving ﬂuconazole monotherapy at 800 to 1,200 mg/day i.v. and orally.
The fAUC:MIC in CSF is shown for each patient. The black and red lines are Bayesian posterior predictions for the total and resistant populations (i.e., able to
grow on agar containing 32 mg/liter ﬂuconazole), respectively. Similarly, the black and red crosses are the observations from total and resistant populations
from each patient, respectively. No patients died within the study period. Patients whose baseline, pretreatment isolates were found to have a resistant
subpopulation growing on ﬂuconazole-containing agar with aneuploidy after whole-genome sequencing are marked with an asterisk. The patients here (and
those described previously by Stone et al. [13]) are designated patients A (patient 001 in the study by Stone et al.), B (002), F (007), G (008), H (009), J (010),
K (011), N (014), O (015), Q (017), and R (18). Note that time zero is the time when the patient initially received ﬂuconazole.
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zole into the CSF, and redeﬁnition of the pharmacodynamics of fungal killing and the
emergence of resistance.
Aneuploidy, particularly duplication of chromosome 1, is consistently observed in
Cryptococcus neoformans following exposure to ﬂuconazole. This mechanism is appar-
ent in in vitro and murine models (12) as well as in patients with cryptococcal
meningitis (13). Aneuploidy may result in ﬂuconazole resistance via increased expres-
sion of the ERG11 (drug target) and AFR1 (efﬂux pump) genes, both of which are located
on chromosome 1 (13). There are two possible scenarios that lead to the emergence of
resistance and dominance of a clone with aneuploidy. First, there may be an expansion
of a subpopulation present prior to ﬂuconazole therapy (i.e., heteroresistance). The expan-
sion is enabled by the killing of a ﬂuconazole-susceptible subpopulation and growth (or
persistence) of a resistant subpopulation. This pattern was exhibited in the hollow-ﬁber
experiments where the resistant subpopulation present prior to ﬂuconazole treatment
progressively expanded and ultimately formed the majority of the fungal population.
This is a function of whether the fungal density at treatment initiation is greater than
the mutational frequency of resistance. In mice, for instance, the estimated burden
FIG 5 Summary of the Monte Carlo simulations constructed using the PK-PD data from the clinical study
in Fig. 4. The 5th, 25, 50th, 75th, and 95th percentiles of the simulated population for the total fungal
burden are shown (A), along with those of a resistant subpopulation growing on agar containing
ﬂuconazole at 32 mg/liter (B). The gray-shaded areas show the 95% conﬁdence intervals around each
percentile. A total of 12.8% of simulated patients are predicted to have sterilized CSF for total and
resistant populations of C. neoformans. Resistant colonies were detectable (log10 CFU of 1) at various
densities in 83.4% of patients.
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in brain at the time of treatment initiation was approximately 100 CFU/g cerebrum
(Table 1), which is well below the mutational frequency. This may explain why resis-
tance did not emerge in all murine experiments but could potentially be circumvented
by inoculation directly into the CNS. In the second scenario, there may be a develop-
ment of de novo resistance (albeit with the same molecular mechanism). The second
scenario may occur without the presence of a resistant subpopulation prior to drug
exposure.
Aneuploidy formation is a general Hsp90 stress-induced phenomenon in eu-
karyotes, including fungi, capable of fueling rapid phenotypic evolution, for which drug
resistance is just one phenotype (21). The emergence of chromosome 1 aneuploidy that
was also seen in vehicle-treated controls supports this hypothesis. Fluconazole has
been shown to promote aneuploidy in both Candida albicans and C. neoformans, albeit
via different mechanisms, resulting in reduced antifungal susceptibility (22–24). Flu-
conazole treatment induced the formation of chromosome 1 disomy by the end of the
experiment using the H99 reference strain in both the HFIM and murine models, and
chromosome 1 disomy was the most commonly emergent aneuploidy in the ﬂuconazole-
treated clinical cohort (13). There are some challenges in deﬁnitively linking the emergence
of resistance (as deﬁned by growth on drug-containing media) with aneuploidy. Selecting
colonies from drug-free media risks missing a resistant subpopulation with aneuploidy.
Conversely, selecting colonies from drug-containing media may lead to erroneous conclu-
sions if the presence of ﬂuconazole induces aneuploidy, but the primary reason for
resistance was an alternative mechanism.
The plasticity and instability of both resistance genotype and phenotype have
hampered attempts to understand the links between ﬂuconazole drug exposure,
microbiological failure, and the emergence of antifungal resistance. Such plasticity is
difﬁcult to model using current PK-PD paradigms where the MIC is assumed to be
invariant. Previous studies have largely failed to demonstrate a relationship between
ﬂuconazole MIC for C. neoformans and clinical outcomes (14, 25–27). Retesting of
clinical isolates from patients failing ﬂuconazole therapy with high MICs generally
results in MICs in the wild-type range. Moreover, there are likely to be differences in
MICs according to whether microdilution or the Etest is used. We found that isolates
retested using broth microdilution following frozen shipment and a single passage had
on average 2- to 4-fold-lower MICs than those originally tested in Tanzania using the
Etest. These discrepancies pose a challenge to the construction of PK-PD relationships
and PK-PD bridging studies with conclusions dependent on MIC methodology and the
way in which the isolate is prepared prior to testing.
This study has several limitations. Only a single challenge strain was used for the
HFIM and murine studies. The clinical data set was relatively small, with fewer patients
still with a full complement of PK-PD data. Resistance was deﬁned as a dichotomous
event (ability to grow on medium containing 32 mg/liter ﬂuconazole) when, in reality,
there is a population of patients infected with cryptococcal isolates with a range of
MICs. While chromosome 1 disomy in H99 consistently emerged in all contexts, additional
aneuploidies were also observed. Furthermore, as-yet-undeﬁned mechanisms other than
aneuploidy may be present (13). The clinical PK-PD analysis was exclusively based on
ﬂuconazole concentrations in CSF, which is only one subcompartment in the central
nervous system. The clinical pharmacodynamics of ﬂuconazole for fungal infection
within the cerebrum remain difﬁcult to deﬁne but may be reasonably different from
those in CSF and ultimately may have a signiﬁcant impact on clinical outcomes (28).
Despite ﬂuconazole being a safe, widely available, and highly orally bioavailable
antifungal agent with extensive partitioning into CSF, the antifungal activity of ﬂucona-
zole for cryptococcal meningitis is compromised by the emergence of resistance. This
is a dynamic, intrinsic property that may be poorly predicted by standard MIC testing
at the initiation of treatment. Dosage escalation may be required to achieve sufﬁcient
exposure to suppress the resistant subpopulation, but the clinical efﬁcacy and tolera-
bility of such a strategy require further study. Combination chemotherapy is an
additional way in which the emergence of resistance can be addressed, but clinical
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choices are currently limited to 5FC. The applicability of our ﬁndings to other triazoles,
such as posaconazole, voriconazole, and isavuconazole, or other compounds that
utilize 14--demethylase as their target (e.g., VT1598) is unknown. Our ﬁndings under-
score the urgent need for the development of new agents and combinations to reduce
the global toll of cryptococcal meningitis.
MATERIALS AND METHODS
Strains of C. neoformans and in vitro susceptibility to ﬂuconazole. H99 (ATCC 208821) was used
as the challenge strain for the hollow-ﬁber infection models and the murine model of meningoenceph-
alitis. The MICs of ﬂuconazole against H99 (ATCC 208821) and the clinical isolates were estimated using
broth microdilution methodology of the Clinical and Laboratory Standards Institute (17).
Hollow-ﬁber infection model. A recently described hollow-ﬁber infection model (HFIM) of crypto-
coccal meningitis was used. Brieﬂy, hollow-ﬁber cartridges (FiberCell Systems, Frederick, MD, USA) were
used and conﬁgured as previously described (16). The extracapillary space of each cartridge was inoculated
with 40 ml of a suspension containing approximately 6 log10 CFU/ml of C. neoformans var. grubii (ATCC
208821; H99). Yeast extract-peptone-dextrose (YPD) medium was pumped from the central compartment
through the cartridge and back again using a peristaltic pump (205 U; Watson-Marlow, United Kingdom).
The HFIM was incubated at 37°C in ambient air. Human-like concentration-time proﬁles in CSF were
simulated and designed to encapsulate the pharmacodynamics of antifungal activity and the emergence
of resistance. The time course of fungal growth was determined by removing 1 ml from the extracapillary
space of the cartridge and plating serial 10-fold dilutions onto both drug-free YPD agar and YPD agar
containing 32 and 64 mg/liter ﬂuconazole.
Murine model of meningoencephalitis. A well-characterized murine model of disseminated infec-
tion was used. Male CD1 mice weighing approximately 25 g at the time of the experiment were injected
i.v. with 0.2 ml of a phosphate-buffered saline (PBS) suspension containing 3 108 CFU/ml (i.e., inoculum
of 6 107 CFU per mouse). No immunosuppression was used because mice are intrinsically susceptible
to invasive infection caused by C. neoformans.
The in vivo pharmacokinetic (PK) studies were performed on infected mice using 125 and 250 mg/
kg/day. Treatment with ﬂuconazole commenced at 24 h postinoculation. Fluconazole was administered
daily by oral gavage. A serial-sacriﬁce design was used to deﬁne the PK. Blood was collected by cardiac
puncture under anesthesia with 1% isoﬂurane, followed by CO2 asphyxia. Plasma was obtained by
centrifugation and stored at80°C until analysis. Plasma samples were obtained at 0.5, 1, 2, 4, 6, and 24 h
postdose in the ﬁrst (i.e., 24 to 48 h postinoculation) and third (i.e., 72 to 96 h postinoculation) dosing
intervals. Following sacriﬁce, the cerebrum was removed, homogenized in PBS, and stored at80°C until
analysis.
For the in vivo murine pharmacodynamic studies, groups of 3 mice were sacriﬁced immediately
postinoculation and then at 24, 48, 96, 144, 192, and 240 h postinoculation. The cerebrum was removed
and plated onto drug-free agar and agar containing ﬂuconazole at 32 mg/liter.
Clinical study. A clinical PK-PD study was performed at the Muhimbili National Hospital in Dar es
Salaam, Tanzania, as a run-in study to the ACTA trial, which was recently reported (29). Ethical approval
was obtained from the National Institute of Medical Research (NIMR) in Tanzania as well as the London
School of Hygiene and Tropical Medicine Ethics Committee (reference number 9176). Informed consent
was obtained from all patients or their guardians. Patients were eligible for enrollment if they were
18 years of age with an initial episode of cryptococcal meningitis, conﬁrmed positive for cryptococcal
antigen (CrAg) in serum or CSF (Immy, Norman, OK), a positive cryptococcal culture, and/or positive India
ink stain in CSF. Patients who were pregnant, unable to receive ﬂuconazole for any reason, or already on
ﬂuconazole therapy for 48 h were excluded. Patients received ﬂuconazole as induction therapy at 800
to 1,200 mg in one or two divided dosages, according to local treatment policies. This was ethically
permissible because in Tanzania, as in much of Africa, the gold-standard induction treatment of
amphotericin B deoxycholate and ﬂucytosine is not available. Induction therapy with ﬂuconazole is the
standard of care for cryptococcal meningitis and all other clinical forms of cryptococcosis.
Consent was sought for plasma sampling at multiple time points. Because permission for intensive
preplanned sampling was often refused, the majority of plasma samples were acquired opportunistically
when samples were obtained as part of routine care. Patients consented to lumbar punctures (LPs) at
baseline and at days 7 and 14 of treatment. Additional LPs were performed if clinically indicated for the
management of raised intracranial pressure. These samples were processed for PK and microbiological
analysis. For every CSF sample, the magnitudes (log10 CFU per milliliter of CSF) of the total fungal density
and the density of the resistant subpopulation were quantiﬁed by directly plating CSF onto drug-free and
ﬂuconazole-containing agar plates at a ﬁnal concentration of 32 mg/liter as previously described (13).
Samples of plasma and CSF for measurement of ﬂuconazole were prepared by centrifugation. The
resultant supernatant was stored at 80°C before being shipped to the University of Liverpool for
measurement of ﬂuconazole concentrations. C. neoformans MIC determinations were performed on-site
using the ﬂuconazole Etest (bioMérieux, Boston, MA) and subsequently using broth microdilution as
described above.
Measurement of ﬂuconazole in experimental and clinical samples. Fluconazole concentrations
were measured using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS)
method with a 1260 Agilent ultraperformance liquid chromatography (UPLC) system coupled to an
Agilent 6420 Triple Quad mass spectrometer (Agilent Technologies UK Ltd., Cheshire, UK). Brieﬂy,
ﬂuconazole was extracted by protein precipitation: 300 l of cold methanol containing the internal
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standard ﬂuconazole-D4 at 0.625 mg/liter (TRC, Canada) was added to 10 l of the sample (plasma or
CSF). The solution was vortex mixed for 5 s and ﬁltered through a Sirocco precipitation plate (Waters Ltd.,
Cheshire, UK). One hundred ﬁfty microliters of the supernatant was transferred to a 96-well autosampler
plate, and 3 l was injected into an Agilent Zorbax C18 rapid resolution high deﬁnition (RRHD) (2.1 by
50 mm; 1.8 m) (Agilent Technologies UK Ltd., Cheshire, UK).
Chromatographic separation was achieved using a gradient consisting of 70% mobile phase A–30%
mobile phase B (0.1% formic acid in water as mobile phase A and 0.1% formic acid in methanol as mobile
phase B). The organic phase was increased to 100% over 90 s, with an additional 90 s of equilibration.
The mass spectrometer was operated in a multiple-reaction-monitoring scan mode in positive
polarity. The precursor ions were m/z 307.11 and m/z 311.1 for ﬂuconazole and the internal standard,
respectively. The product ions for ﬂuconazole were m/z 220.1 and m/z 238.1, and those for the internal
standard were m/z 223.2 and m/z 242.1. The source parameters were set as follows: capillary voltage of
4,000 V, gas temperature of 300°C, and nebulizer gas at 15 lb/in2.
The standard curve for ﬂuconazole encompassed the concentration range of 1 to 120 mg/liter and
was constructed using a blank matrix. The limit of quantitation was 1 mg/liter. In plasma, the intraday
coefﬁcient of variation (CV) was 3.4%, and the interday CV was 6.7%, over the concentration range
of 1 to 90 mg/liter. In CSF, the intraday CV was 5.2%, and the interday CV was 5.3% over the same
concentration range.
Sequencing and bioinformatics. Genomic DNA was extracted using the MasterPure yeast DNA
puriﬁcation kit (Epicentre, Madison, WI). Following resuspension in lysis buffer and the addition of RNase,
two rounds of cell disruption were performed using a FastPrep homogenizer and lysing matrix C (MP
Biomedicals, Solon, OH). The resulting lysate was centrifuged at 12,000 g for 2 min, and the superna-
tant was heated at 65°C for 15 min. Protein precipitation and DNA recovery were performed according
to the manufacturer’s instructions. A further round of RNase treatment was performed, and DNA was
puriﬁed using the genomic DNA clean and concentrator kit (Zymo Research, Irvine, CA).
Libraries were constructed from submitted samples using the Illumina TruSeq Nano DNA HT library
prep kit. Brieﬂy, 100 ng DNA for each sample was sheared to an average of 350 bp using the Bioruptor
Pico sonicator (Diagenode) and cleaned, and the products were A tailed by incubation at 37°C for 30 min
and ligated to dual-ended adapters at 30°C for 10 min. Template DNA was diluted to 3 nM, 5 l was
denatured for 8 min at room temperature using 5 l freshly diluted 0.1 N sodium hydroxide (NaOH), and
the reaction was subsequently terminated by the addition of 5 l 0.1 M Tris Cl (pH 8). The ﬁnal loading
concentration of 300 pM was reached by adding 35 l exclusion ampliﬁcation enzyme mix. Clustering of
DNA templates was performed using a HiSeq 3000/4000 paired-end (PE) cluster kit with a cBot cluster
generation system (Illumina), according to the manufacturer’s instructions. Following cluster generation,
libraries were sequenced on an Illumina HiSeq 4000 instrument (Illumina) with version 1 chemistry using
sequencing-by-synthesis (SBS) technology to generate 2- by 150-bp paired-end reads.
A total of 34 samples (n 15 for the murine study and n 19 for the HFIM) were sequenced on the
Illumina HiSeq4000 platform (2- by 150-bp paired-end reads) (Illumina, Inc., San Diego, CA) by the Centre
for Genomic Research (https://www.liverpool.ac.uk/genomic-research), University of Liverpool, UK. Base
calling and demultiplexing of indexed reads were performed by using CASAVA version 1.8.2 (Illumina,
Inc., San Diego, CA) to produce the raw sequence data in FASTQ format. The raw FASTQ reads were
trimmed to remove Illumina adapter sequences using Cutadapt version 1.2.1 (30) and low-quality bases
using Sickle version 1.200 (31).
Trimmed reads were aligned to the Cryptococcus neoformans var. grubii H99 reference genome
(https://fungi.ensembl.org/Cryptococcus_neoformans_var_grubii_h99/Info/Index) with the short-read
alignment tool BWA-MEM (version 0.7.5a-r405) (32). Following alignment, PCR and optical duplicate
reads were identiﬁed and removed with Picard (version 1.94) (http://broadinstitute.github.io/picard).
Subsequently, the Genome Analysis Toolkit (GATK) (version 3.7) (33) Indel Re-aligner module (34) was
used to locally realign reads around putative insertion and deletion sites. The aligned data were then
analyzed using Control-FREEC (35) to assess chromosomal ploidy.
PK-PD modeling. The clinical PK-PD study was modeled in a 2-step process to try to provide a stable
solution from relatively sparse data. First, the PK was solved using the following sets of inhomogeneous
differential equations that described the transfer of ﬂuconazole from the gut (compartment 1) to the
central bloodstream (compartment 2) and the peripheral compartment (compartment 3) and into the
CSF (compartment 4). Fluconazole was administered either as a bolus [B(1)], as a tablet, or as an i.v.
infusion [R(1)], which enabled bioavailability (F) to be estimated (not shown in the differential equations).
XP1 B1 Ka X1
XP2 R1 Ka X1 SCL ⁄V X2 Kcp X2 Kcp X3 Kcs X2 Ksc X4
XP3 Kcp X2 Kcp X3
XP4 Kcs X2 Ksc X4
The model outputs are denoted by Y(1) and Y(2), and the two output equations are denoted by
Y1 X2 ⁄V
Y2 X4 ⁄Vcsf
with the ﬁrst and second output equations representing the time course of plasma and CSF concentra-
tions of ﬂuconazole, respectively. The amount of drug in compartment 1, 2, 3, and 4 is denoted by X(1),
X(2), X(3), and X(4), respectively. Similarly, the rate of change of amount in each compartment is denoted
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by XP(1), XP(2), XP(3), and XP(4), respectively. The fAUC in plasma and CSF was calculated using
integration from the Bayesian posterior parameter values.
The median Bayesian posterior estimates described each individual patient well. These were obtained
and ﬁxed for the pharmacodynamic modeling below. For pharmacodynamic modeling, the following
model was used. The ﬁrst 4 equations are the same as the ones described above and describe the PK in
the gut, plasma, peripheral compartment, and CSF. The time courses of the densities of the susceptible
and resistant subpopulations are described by the ﬁfth and sixth equations, respectively. The structure
of these equations differed slightly. The growth of a susceptible population was not observed (since it
is unethical to withhold therapy). Hence, the density of this subpopulation could only decrease with time
from an initial starting value, which was estimated in the ﬁtting process as an initial condition. In contrast,
both the growth and death of the resistant subpopulation were observed. Hence, the equation contains
a term that describes the capacity for limited growth as well as ﬂuconazole-induced killing that is
explicitly linked to concentrations within the CSF. An initial density of the resistant population was
estimated in the same way as for the susceptible subpopulation.
XP5kkmax_s [X4 ⁄Vcns]**Hks ⁄ {C50k_s**Hk_s [X4 ⁄Vcns]**Hk_s} X5
XP6 Kgmax_r {1.D0 [X6 ⁄ popmax]} X6 kkmax_r
 [X4 ⁄Vcns]**Hk_r ⁄ {C50k_r**Hk_r [X4 ⁄Vcns]**Hk_r} X6
The two output equations for the pharmacodynamics were
Y1 DLOG10[X5 X6]
Y2 DLOG10[X6]
The ﬁrst equation describes the time course of the total population (i.e., susceptible plus resistant). The
second equation describes the time course of the resistant subpopulation. DLOG10 is the logarithm base
10 of the fungal density.
Monte Carlo simulations. Simulations were performed using the linked PK-PD model. Because the
original problem was solved in a two-step process, the PK model was used to generate 100 simulated
patients, each with their own unique set of PK parameters. These simulated patients were then supplied
to the pharmacodynamics portion of the mathematical model, and each set of PK parameters was
then used to generate 100 further simulated patients with pharmacodynamic outputs. Data from
these simulated patients were used to deﬁne the time courses of fungal densities of the total and
resistant subpopulations in the CSF for the 5th, 25th, 50th, 75th, and 95th percentiles of the
simulated population.
SUPPLEMENTAL MATERIAL
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